CSL +0.90%: edged higher today after reporting strong plasma collections and reiterated its full-year guidance for FY23 underlying net profit at about $2.7-$2.8 billion in constant currency terms, which was a touch ahead of current consensus. The momentum in collections (+38%) should drive growth into FY24 and margins were solid, particularly in Seqirus while Vifor is running slightly above expectations. A good update from CSL – keeps us positive.
MM is bullish & long CSL in the Flagship Growth Portfolio
Add To Hit List
